Safety Study of Whole Body Hyperthermia for Advanced Cancer

Advanced Cancer Clinical Trial

— MATTERS  

Official title:

A Mono-centric, First In-human (FIH), Safety and Preliminary Efficacy Study of (Neo)Adjuvant, Model-based, Whole-body Hyperthermia (WBHT) Treatment in Advanced Solid Cancer Patients or Stage IV (TxNxM1) Metastatic Pancreatic Adenocarcinoma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04467593
• Other study ID #: MATTERS 1
• Status: Recruiting
• Phase: N/A
• Start date: July 28, 2021
• Est. completion date: December 2024

Study information

• Verified date: February 2023
• Source: ElmediX
• Contact: Oleg Rudenko, MD MSc
• Phone: +3215262981
• Email: oleg.rudenko[@]elmedix.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Millions of patients die of cancer every year. There are several methods to treat cancer, including surgery, chemotherapy, radiotherapy and immunotherapy. Recently, hyperthermia therapy started playing a role in cancer therapy. It has shown effect in animal experiments and clinical practice. The sponsor has developed a novel device to use hyperthermia for advanced cancer. This study is to prove the safety in human patients of this device & therapy and get the first data on efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

1. Patients between 18- and 75-years of age at time of signing the informed consent

2. Patients with advanced solid cancer (for cohort A1, A2 only) or metastatic pancreatic adenocarcinoma confirmed by histology (for cohort B/C/D only)

3. Patients previously treated or under treatment with standard of care treatment (cohort B/C/D only) or patients without treatment options

4. WHO performance status = 1(see appendix V)

5. Maximum waist circumference = 150 cm

6. Weight = 100 kg

7. Height = 1,90 m

8. Adequate liver structure (confirmed by CT scan) allowing the placement of the liver sensor

9. No (prostate) pathology that would interfere with the placement of the bladder catheter

10. Adequate bone marrow function defined as

1. white blood cell count = 2000/µl

2. neutrophils = 1500 cells/µL

3. platelets = 100 x 109/L

4. hemoglobin = 10 g/dl documented within 1 week prior to first treatment

11. Adequate coagulation defined as

1. PT (%) = 70%

2. aPTT = ULN

3. Von Willebrand Factor Antigen = LLN

4. Von Willebrand Factor Activity = LLN

5. PFA COL/EPI CT = 1.15 ULN

6. PFA COL/ADP CT = 1.15 ULN

12. Adequate liver function defined as

1. Transaminases (AST, ALT) = 2.5 x ULN or = 5.0 in presence of liver metastasis

2. bilirubin = 2 x ULN documented

13. Adequate renal function defined as

1. serum creatinine = 1.6 mg/dL (male); = 1.3 mg/dL (female);

2. albumin = 30g/L

3. calculated eGFR = 60 mL/min (CKD-EPI equation) documented within 1 week prior to randomization

14. No blood donation 3 months prior to the WBHT treatment

15. No participation in other clinical trial 4 weeks prior to the WBHT treatment

16. No biological therapy 4 weeks prior to the WBHT treatment or during WBHT treatment

17. No surgery 4 weeks prior to the WBHT treatment

18. No radiotherapy 3 weeks prior to the WBHT treatment or during WBHT treatment

19. No chemotherapy 1 week prior to the WBHT treatment (for cohort A/B/C/D) or during WBHT treatment (for Cohort A1/A2)

20. No anti-platelet aggregation medication intake from 5 days prior to the first WBHT treatment until 5 days after the last treatment

21. No anticoagulant medication intake between screening and last follow-up visit. However, if deemed necessary by the investigator, the patient may receive prophylactic Low Molecular Weight Heparin on the day prior to the first WBHT treatment until 10 days after the last WBHT treatment

22. No transdermal patches during participation in the study

23. No piercings (internally or externally)during WBHT treatment

24. Life expectancy of at least 18 weeks

25. Effective contraception for both male and female patients if applicable. Women of childbearing potential must have negative blood pregnancy test at screening visit.

26. Written informed consent must be given according to good clinical practice and national/local regulations.

Exclusion criteria:

1. Pregnant or breastfeeding women (based on HCG levels)

2. Presence of brain metastasis (known or suspected)

3. Other malignant diseases in the medical history during the last 5 years (exceptions:

carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin)

4. Serious medical risk factors involving any of the major organ systems, including high cardiovascular risk, coronary stenting or myocardial infarction in the last year

5. Clinically significant pulmonary disease which might interfere with mechanical ventilation

6. History of autonomic dysfunction (due to the influence on skin blood flow)

7. History of malignant hyperthermia or a positive diagnostic test (Caffeine-Halothane Contracture test) in case of family history of malignant hyperthermia.

8. History of untreated endocrine pathology (e.g. diabetes type II, hyper- or hypothyroidism).

9. Primary diabetes type I (due to vascular complications)

10. Known allergies to drugs that will be used during the trial (e.g. anesthetic, analgesic, (chemotherapy used in cohort B/C/D))

11. Active infections not controlled by medication

12. Severe, non-healing wounds, ulcers or bone fractures

13. Organ allografts requiring immunosuppressive therapy

14. (History of) clinically significant (investigator decision) psychiatric disorder and/or psychosocial disorder that may interfere with adequate compliance to the protocol or signature of the informed consent

15. Other clinically significant disease which could impair the patient's ability to participate in the study according to the investigator's opinion

16. Participation in another clinical trial during this trial

Related Conditions & MeSH terms

• Advanced Cancer
• Hyperthermia
• Pancreatic Cancer Metastatic

Intervention

Device:
• Whole body hyperthermia
Whole body hyperthermia to treat stage IV cancer patients

Drug:
• Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy

Locations

Country	Name	City	State
Belgium	University Hospital Antwerp	Edegem	Antwerpen

Sponsors (1)

Lead Sponsor	Collaborator
ElmediX

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse device events (ADEs) in relation to the medical device		4 weeks after last treatment
Primary	Incidence of related clinically significant abnormalities on electrocardiogram (ECG), vital signs, physical examination and laboratory parameters		4 weeks after last treatment
Primary	Incidence of adverse events (AEs) related to WBHT treatment alone or in combination with SOC chemotherapy according to the NCCN guidelines. nab-paclitaxel or gemcitabine alone		4 weeks after last treatment
Secondary	evolution of CA19-9 (U/ml)	The evolution of this clinically significant biological parameter will be measured compared to baseline	4 weeks after last treatment
Secondary	evolution of CEA (ng/ml)	The evolution of this clinically significant biological parameter will be measured compared to baseline	4 weeks after last treatment
Secondary	based on the three primary outcome measures, guidance will be drafted for phase II treatment duration in combination with chemotherapy dosing.		4 weeks after last treatment